Beghi E, Pupillo E, Bonito V, Buzzi P, Caponnetto C, Chi A, Corbo M, Giannini F, Inghilleri M, Bella VL, Logroscino G, Lorusso L, Lunetta C, Mazzini L, Messina P, Mora G, Perini M, Quadrelli ML, Silani V, Simone IL, Tremolizzo L
Depicts MTHFR variant activity For example, an individual who is heterozygous at both C677T (C/T) and A1298C (A/C), known as a compound heterozygote, is expected to exhibit a 55% decrease in MTHFR enzymatic activity (35% activity due to the presence of one T allele at C677T and 20% activity due to the presence of one C allele at A1298C = 55%)
Patients should evaluate the evidence base for a specific compound and a specific purpose separately from its regulatory posture
Since compounded medications dont always have standardized expiration dates, its understandable to have concerns about shelf life, potency, and safety